Summary & Overview

Cranial and Peripheral Nerve Disorders without MCC: Inpatient Reimbursement Overview

DRG 074 groups inpatient stays for cranial and peripheral nerve disorders without Major Complication or Comorbidity, encompassing conditions like compressive neuropathies and select cranial nerve dysfunctions. This grouping matters for inpatient reimbursement because it determines case classification, relative resource use, and the Medicare payment weight applied to qualifying admissions.

Cranial and Peripheral Nerve DisordersDRG Cranial and Peripheral Nerve Disorders without MCCDRG 074Diagnosis-Related GroupInpatient ReimbursementMedicareNeurosurgeryNeurologyNerve CompressionHospital Billing

DRG 074 Overview

DRG 074 covers inpatient admissions for cranial and peripheral nerve disorders without a Major Complication or Comorbidity. It includes diagnoses such as nerve compressions, neuropathies, and certain cranial nerve disorders when the clinical course is uncomplicated. This Diagnosis-Related Group is used to classify cases for Medicare inpatient payment and influences base payment rates and resource expectations. Understanding this DRG helps clarify reimbursement implications for hospital stays that do not involve major complications.

National Payment Rates

Across featured payers the observed rate range runs roughly from $370 up to $35K, with the widest spread between Anthem (min $390, max $35K) and other payers reflecting a high dispersion. Commercial benchmarks show median payments clustered between about $9.3K and $18K depending on payer, while maximums extend into the high $20Ks to mid $30Ks. See the table and chart below for payer-specific quartiles and distributions.

Mean Rates by Payer — National — DRG 074

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska payer rates for DRG 074 span from 16K to 25K across the reported payers, with Blue Cross Blue Shield and Anthem at the low end (16K) and Cigna at the high end (25K). The Cigna mean notably exceeds the other in-state payers and sits above many national averages, creating the most pronounced deviation. Reference the table and chart below for payer-level detail.

Key Insights for Alaska

Highest payer: Cigna with a mean of 25K; Lowest payer(s): BCBS and Anthem, both with a mean of 16K.
Cigna’s mean (25K) in Alaska is meaningfully above the state’s other payers and above national means for several payers, indicating a notable upward deviation from national averages.

Clinical Trials

Acute neuromodulation and surgical intervention trials: studies in this area evaluate the safety and short-term efficacy of acute surgical or neuromodulatory procedures (for example, decompression, nerve repair, or intraoperative monitoring-guided interventions) for patients admitted with cranial nerve palsies, traumatic peripheral nerve injury, or compressive neuropathies causing hospital-level symptoms. These trials typically enroll patients during the index hospitalization or immediately post-injury to measure time-to-recovery, complication rates, and need for reoperation, addressing questions about optimal timing and technique. Results inform surgeons, hospitalists, and payers about procedure-related resource use, length of stay implications, and early outcomes that drive inpatient reimbursement and bundle payment considerations.
Comparative effectiveness and perioperative management studies: these trials compare different non-surgical or adjunctive inpatient therapies (such as corticosteroid regimens, anticoagulation strategies when vascular causes are suspected, or different anesthesia/monitoring approaches) for acute cranial and peripheral nerve disorders. They enroll heterogeneous inpatient populations—patients with Bell’s palsy variants, ischemic cranial neuropathies, or acute compressive neuropathies—to determine which management pathways shorten neurologic deficit duration, reduce complications, or lower readmission. Findings are relevant to clinicians and payers because they identify care pathways that optimize outcomes while potentially reducing length of stay, avoidable imaging or consultations, and overall inpatient costs.
Post-discharge functional outcomes and rehabilitation trials: these studies focus on subacute and longer-term recovery, testing timing and intensity of rehabilitation interventions (physical therapy, occupational therapy, specialized nerve rehabilitation programs) or care-coordination models for patients discharged after an acute cranial or peripheral nerve event. They target patients with residual motor or sensory deficits after hospital discharge and measure functional recovery, quality of life, and downstream health-care utilization such as outpatient therapy needs, readmissions, or durable medical equipment. Evidence from these trials helps payers and providers plan post-acute services, allocate rehabilitation resources, and predict long-term costs associated with incomplete recovery in this DRG.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$10K	$51K	$7.8K	12K

Acute neuromodulation and surgical intervention trials: studies in this area evaluate the safety and short-term efficacy of acute surgical or neuromodulatory procedures (for example, decompression, nerve repair, or intraoperative monitoring-guided interventions) for patients admitted with cranial nerve palsies, traumatic peripheral nerve injury, or compressive neuropathies causing hospital-level symptoms. These trials typically enroll patients during the index hospitalization or immediately post-injury to measure time-to-recovery, complication rates, and need for reoperation, addressing questions about optimal timing and technique. Results inform surgeons, hospitalists, and payers about procedure-related resource use, length of stay implications, and early outcomes that drive inpatient reimbursement and bundle payment considerations.
Comparative effectiveness and perioperative management studies: these trials compare different non-surgical or adjunctive inpatient therapies (such as corticosteroid regimens, anticoagulation strategies when vascular causes are suspected, or different anesthesia/monitoring approaches) for acute cranial and peripheral nerve disorders. They enroll heterogeneous inpatient populations—patients with Bell’s palsy variants, ischemic cranial neuropathies, or acute compressive neuropathies—to determine which management pathways shorten neurologic deficit duration, reduce complications, or lower readmission. Findings are relevant to clinicians and payers because they identify care pathways that optimize outcomes while potentially reducing length of stay, avoidable imaging or consultations, and overall inpatient costs.
Post-discharge functional outcomes and rehabilitation trials: these studies focus on subacute and longer-term recovery, testing timing and intensity of rehabilitation interventions (physical therapy, occupational therapy, specialized nerve rehabilitation programs) or care-coordination models for patients discharged after an acute cranial or peripheral nerve event. They target patients with residual motor or sensory deficits after hospital discharge and measure functional recovery, quality of life, and downstream health-care utilization such as outpatient therapy needs, readmissions, or durable medical equipment. Evidence from these trials helps payers and providers plan post-acute services, allocate rehabilitation resources, and predict long-term costs associated with incomplete recovery in this DRG.

OpenPayer

Summary & Overview

Cranial and Peripheral Nerve Disorders without MCC: Inpatient Reimbursement Overview

DRG 074 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes